← All trials
NCT04559217
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2020
- Primary completion
- Nov 15, 2026
- Completion date
- Aug 30, 2027
- First posted
- Sep 22, 2020
- Last posted
- Sep 22, 2020
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of SherbrookeLead sponsor
- Ciusss de L'Est de l'Île de MontréalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.